| Abbott Labs to Buy Indian Drug Maker Abbott Laboratories will buy Piramal Healthcare's healthcare solutions business for a total of $3.72 billion, boosting its presence in India. online.wsj.com |
Dr. Reddy's Profit Retreats 14% Indian drug maker Dr. Reddy's reported a steeper-than-expected 14% drop in first-quarter consolidated net profit, dragged down mainly by lower sales in the North American market. online.wsj.com |
U.S. Mulls St. Jude Complaint The U.S. Justice Department said it wants to intervene in a lawsuit against St. Jude Medical in which a former worker accused the heart-device maker of using medical studies to pay kickbacks and boost product usage. online.wsj.com |
Why Next-Gen Biofuels Look Attractive for Biotech Investors The Burrill Report submits: By John Hamer It’s interesting that biotech publications focused on healthcare have reported the news of the Amyris (AMRS) IPO, a next-generation biofuel company. Biotech investors will probably look seriously at this area. Much of the underlying technology, such as genomics and synthetic biology, is shared with traditional biotechs. The first two companies out of the chute, Amyris and Codexis (CDXS), also have healthcare-related projects. What do next-generation biofuel companies offer the biotech investor? Complete Story » seekingalpha.com |
GE expands into molecular testing [at Financial Times] - General Electric has agreed to purchase Clarient, a molecular testing company, for about $580m in cash as it seeks to expand into the growing market for products and tests that analyse cancers. us.rd.yahoo.com |